Newsletter

Newsletter July 2020

We are currently experiencing technical problems with our electronical distribution of newsletters I am delighted to present my first newsletter as CEO for Cyxone. The first month in the company has been intense, exciting and interesting. I am busy getting to know the company’s projects and partners with support from an excellent team of skilled […]

Read More

Newsletter December 2019

Read in web browser CEO comments The recent past has been very eventful. Important intermediary goals have been achieved in the development processes of both Rabeximod and T20K. Much is ongoing within the organization and we are in the process of recruiting a new CEO to take Cyxone further into the expansive phase we are […]

Read More

Newsletter November 2019

Read in web browser CEO comments As the days get shorter and the darkness falls earlier and earlier for each day, I am very happy about the many good news that has come to characterize Cyxone lately, which is also reflected in this newsletter. Most central is among other things the successful TO3 that expired […]

Read More

Newsletter September 2019

Read in web browser CEO comments During the recent months, we have been able to communicate milestones that we, together with our collaboration partners, have worked hard to fulfill. Both T20K and Rabeximod have during summer taken strong steps forward in their respective development plans in accordance with objectives set during our preparatory work in […]

Read More

Newsletter June 2019

Read in web browser CEO comments At last, it has finally become time to resume communication with your shareholders via newsletters. Cyxone has kept a low profile while we prepared for our clinical studies and now, when we have reached clinical development with both of our candidates, we can finally start sharing more about what […]

Read More